Kempen JH, et al. Am J Ophthalmol. 2015;doi:10.1016/j.ajo.2015.09.017.

December 29, 2015
1 min read

MUST trial outlines predictive factors to guide uveitis treatment


Kempen JH, et al. Am J Ophthalmol. 2015;doi:10.1016/j.ajo.2015.09.017.

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Standard-of-care treatment seems to stabilize or improve most cases of intermediate uveitis, posterior uveitis and panuveitis, according to a study.

The Multicenter Uveitis Steroid Treatment (MUST) trial followed 479 eyes with intermediate, posterior and panuveitis of 255 patients for 2 years to identify factors predictive of visual outcomes to help guide treatment decisions.

Significantly lower best corrected visual acuity was associated with patients aged 50 years or older; posterior uveitis; uveitis diagnosed more than 10 years ago vs. less than 6 years ago; detectable anterior chamber flare; and cataract, macular thickening and exudative retinal detachment.

Four hundred twenty-nine eyes completed the full 2 years of follow-up. Sixty-two eyes with a baseline BCVA of 20/200 or worse had a mean gain of 20.2 letters at 2 years, while 113 eyes with BCVA between 20/50 and 20/200 had a mean gain of 9.9 letters, and 254 eyes with BCVA better than 20/50 had a mean of 1 letter.

Both systemic and fluocinolone acetonide implant treatment tended to result in favorable outcomes in all cases.

Improved BCVA was associated with resolution of active anterior chamber cells, resolution of macular thickening and occurrence of cataract surgery.

Worsened BCVA was associated with a longer duration of uveitis, incident anterior chamber flare, baseline and follow-up cataract, baseline pseudophakia, persistence or incidence of vitreous haze, and incidence of macular thickening. – by Kristie L. Kahl

Disclosure: Kempen reports he has been a consultant for AbbVie, Alcon, Allergan, Can-Fite, Clearside, Lux Biosciences, Roche and Xoma. Please see the full study for a list of all other authors’ relevant financial disclosures.